Cargando…
SARS-CoV-2 Serology Testing in an Asymptomatic, At-Risk Population: Methods, Results, Pitfalls
The primary aim of this study was to determine the seroprevalence of SARS-CoV-2 antibodies in a population of pediatric healthcare workers (HCWs). This study was conducted 14 May–13 July 2020. Study participants included pediatric HCWs at a pediatric hospital with either direct patient contact or cl...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544562/ https://www.ncbi.nlm.nih.gov/pubmed/34698190 http://dx.doi.org/10.3390/idr13040082 |
_version_ | 1784589845623996416 |
---|---|
author | Heyming, Theodore Bacon, Kellie Lara, Bryan Knudsen-Robbins, Chloe Tongol, Aprille Sanger, Terence |
author_facet | Heyming, Theodore Bacon, Kellie Lara, Bryan Knudsen-Robbins, Chloe Tongol, Aprille Sanger, Terence |
author_sort | Heyming, Theodore |
collection | PubMed |
description | The primary aim of this study was to determine the seroprevalence of SARS-CoV-2 antibodies in a population of pediatric healthcare workers (HCWs). This study was conducted 14 May–13 July 2020. Study participants included pediatric HCWs at a pediatric hospital with either direct patient contact or close proximity to patient-care areas. SARS-CoV-2 antibodies were assessed via the Wytcote Superbio SARS-CoV-2 IgM/IgG Antibody Fast Detection Kit and the Abbott Architect SARS-CoV-2 IgG assay. Participants underwent RT-PCR testing upon entry to the study and following rapid IgM+/IgG+ results; respiratory panel PCR (RP-PCR) was performed following IgM+ results. A total of 57 of 289 (19.7%) of participants demonstrated positive serology as assessed by the Wytcote rapid kit (12 on Day 1 and 45 throughout the study). However, only one of these participants demonstrated IgG+ serology via the Abbott assay. Two participants tested SARS-CoV-2+ via RT-PCR testing. One individual was adenovirus+ and enterovirus/rhinovirus+. In our study population, we observed a seroprevalence of SARS-CoV-2 antibodies of 0.35%. The lack of concordance between antibody tests suggests that the Wytcote rapid test kit may not be of use as a screening tool. However, the feasibility of the overall process indicates that a similar methodology may have potential for future epidemiologic surveillance. |
format | Online Article Text |
id | pubmed-8544562 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85445622021-10-26 SARS-CoV-2 Serology Testing in an Asymptomatic, At-Risk Population: Methods, Results, Pitfalls Heyming, Theodore Bacon, Kellie Lara, Bryan Knudsen-Robbins, Chloe Tongol, Aprille Sanger, Terence Infect Dis Rep Article The primary aim of this study was to determine the seroprevalence of SARS-CoV-2 antibodies in a population of pediatric healthcare workers (HCWs). This study was conducted 14 May–13 July 2020. Study participants included pediatric HCWs at a pediatric hospital with either direct patient contact or close proximity to patient-care areas. SARS-CoV-2 antibodies were assessed via the Wytcote Superbio SARS-CoV-2 IgM/IgG Antibody Fast Detection Kit and the Abbott Architect SARS-CoV-2 IgG assay. Participants underwent RT-PCR testing upon entry to the study and following rapid IgM+/IgG+ results; respiratory panel PCR (RP-PCR) was performed following IgM+ results. A total of 57 of 289 (19.7%) of participants demonstrated positive serology as assessed by the Wytcote rapid kit (12 on Day 1 and 45 throughout the study). However, only one of these participants demonstrated IgG+ serology via the Abbott assay. Two participants tested SARS-CoV-2+ via RT-PCR testing. One individual was adenovirus+ and enterovirus/rhinovirus+. In our study population, we observed a seroprevalence of SARS-CoV-2 antibodies of 0.35%. The lack of concordance between antibody tests suggests that the Wytcote rapid test kit may not be of use as a screening tool. However, the feasibility of the overall process indicates that a similar methodology may have potential for future epidemiologic surveillance. MDPI 2021-10-21 /pmc/articles/PMC8544562/ /pubmed/34698190 http://dx.doi.org/10.3390/idr13040082 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Heyming, Theodore Bacon, Kellie Lara, Bryan Knudsen-Robbins, Chloe Tongol, Aprille Sanger, Terence SARS-CoV-2 Serology Testing in an Asymptomatic, At-Risk Population: Methods, Results, Pitfalls |
title | SARS-CoV-2 Serology Testing in an Asymptomatic, At-Risk Population: Methods, Results, Pitfalls |
title_full | SARS-CoV-2 Serology Testing in an Asymptomatic, At-Risk Population: Methods, Results, Pitfalls |
title_fullStr | SARS-CoV-2 Serology Testing in an Asymptomatic, At-Risk Population: Methods, Results, Pitfalls |
title_full_unstemmed | SARS-CoV-2 Serology Testing in an Asymptomatic, At-Risk Population: Methods, Results, Pitfalls |
title_short | SARS-CoV-2 Serology Testing in an Asymptomatic, At-Risk Population: Methods, Results, Pitfalls |
title_sort | sars-cov-2 serology testing in an asymptomatic, at-risk population: methods, results, pitfalls |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544562/ https://www.ncbi.nlm.nih.gov/pubmed/34698190 http://dx.doi.org/10.3390/idr13040082 |
work_keys_str_mv | AT heymingtheodore sarscov2serologytestinginanasymptomaticatriskpopulationmethodsresultspitfalls AT baconkellie sarscov2serologytestinginanasymptomaticatriskpopulationmethodsresultspitfalls AT larabryan sarscov2serologytestinginanasymptomaticatriskpopulationmethodsresultspitfalls AT knudsenrobbinschloe sarscov2serologytestinginanasymptomaticatriskpopulationmethodsresultspitfalls AT tongolaprille sarscov2serologytestinginanasymptomaticatriskpopulationmethodsresultspitfalls AT sangerterence sarscov2serologytestinginanasymptomaticatriskpopulationmethodsresultspitfalls |